Prognostic value of circulating tumor markers in patients with Pseudomyxoma Peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Prognostic value of circulating tumor markers in patients with Pseudomyxoma Peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
复制标题
DOI：
10.1245/s10434-007-9393-9
复制
发表时间：
2007-08-01
影响因子：
3.7
通讯作者：
Deraco, Marcello
中科院分区：
文献类型：
--
作者：
Baratti, Dario;Kusamura, Shigeki;Deraco, Marcello
背景：最近报道了一些腹膜假性粘液瘤(PMP)患者接受细胞减灭术(CRS)和腹膜内高温化疗(HIPEC)治疗的令人鼓舞的结果。预测临床结果的选择因素仍然是临床研究的问题。我们评估了一大系列接受CRS和HIPEC的PMP患者血清肿瘤标志物的预后可靠性。方法：62名PMP患者在一家机构接受手术，目的是进行足够的CRS(残存肿瘤结节)
Background: Encouraging results have been recently reported in selected patients affected by pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The selection factors predicting clinical outcome are still a matter of clinical investigation. We assessed the prognostic reliability of serum tumor markers in a large series of patients with PMP undergoing CRS and HIPEC.Methods: Sixty-two patients with PMP were operated on at a single institution with the intent of performing adequate CRS (residual tumor nodules